Search
Dec 16, 2024
Syndax's CEO Michael Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more
He describes being first to market in the menin inhibitor space and the advantage he believes that gives Syndax, and he highlights other...
Dec 12, 2023
Recapping #ASH23 with Syndax CEO Michael Metzger
Syndax's CEO reviews late breaking data on the menin inhibitor revumenib in KMT2A-rearranged leukemias and discusses axatilimab's GvHD data.
.png){kind=logo}
